MCID: SBP004
MIFTS: 46

Subependymoma

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Subependymoma

MalaCards integrated aliases for Subependymoma:

Name: Subependymoma 53 59 55
Subependymal Glioma 73

Characteristics:

Orphanet epidemiological data:

59
subependymoma
Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251639
UMLS via Orphanet 74 C0206725
ICD10 via Orphanet 34 D43.2
UMLS 73 C0206725

Summaries for Subependymoma

NIH Rare Diseases : 53 Subependymomas are slow-growing brain tumors that are usually benign. They are most often found in the fourth or lateral ventricles in the brain, but may occur in the spine. Symptoms depend on the tumor location. Some people do not have symptoms, while others may have headaches, changes in vision, and/or difficulty with balance. These symptoms are thought to be due to obstruction of cerebral spinal fluid (CSF) due to the tumor's location. Most subependymomas are benign with a low recurrence rate. However, a few progress to anaplastic ependymoma (a faster growing tumor). The cause of subependymomas is not well understood. Surgery to remove the tumor is often curative.

MalaCards based summary : Subependymoma, also known as subependymal glioma, is related to subependymal glioma and ependymoma, and has symptoms including headache, motor manifestations and sensory manifestations. An important gene associated with Subependymoma is HBG2 (Hemoglobin Subunit Gamma 2), and among its related pathways/superpathways are Neuroscience and Spinal Cord Injury. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 76 A subependymoma is a type of brain tumor; specifically, it is a rare form of ependymal tumor.They are... more...

Related Diseases for Subependymoma

Diseases related to Subependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 subependymal glioma 31.4 ENO2 GFAP SYP TSC2
2 ependymoma 30.2 ENO2 GFAP NES SYP
3 obstructive hydrocephalus 29.9 AQP4 GFAP SYP
4 hydrocephalus 29.9 ENO2 GFAP NES SYP
5 hemangioblastoma 29.9 ENO2 GFAP SYP
6 tanycytic ependymoma 29.6 CHGA GFAP NES SYP
7 central neurocytoma 29.4 CHGA ENO2 GFAP NES SYP
8 glioma susceptibility 1 11.3
9 spinal meningioma 10.3 CHGA ENO2
10 spinal canal and spinal cord meningioma 10.3 CHGA ENO2
11 intracranial hypertension 10.3 AQP1 AQP4
12 dysferlinopathy 10.3 AQP1 AQP4
13 diffuse pulmonary fibrosis 10.3 CHGA ENO2
14 duodenal gastrinoma 10.3 CHGA ENO2
15 granular cell tumor 10.2 ENO2 GFAP
16 dysgerminoma of ovary 10.2 ENO2 GFAP
17 juvenile pilocytic astrocytoma 10.2 ENO2 GFAP
18 intracranial primitive neuroectodermal tumor 10.2 CHGA ENO2
19 pulmonary blastoma 10.2 CHGA SYP
20 tubular adenocarcinoma 10.2 CHGA SYP
21 gastric tubular adenocarcinoma 10.2 CHGA SYP
22 somatostatinoma 10.2 CHGA ENO2
23 non-functioning pancreatic endocrine tumor 10.2 CHGA SYP
24 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA ENO2
25 brain injury 10.2 ENO2 GFAP
26 lung oat cell carcinoma 10.2 CHGA ENO2
27 goblet cell carcinoid 10.2 CHGA ENO2
28 cystadenoma 10.2 CHGA SYP
29 astrocytoma 10.2
30 craniopharyngioma 10.2
31 central pontine myelinolysis 10.2 AQP1 AQP4
32 chondrosarcoma, extraskeletal myxoid 10.2 ENO2 SYP
33 bone benign neoplasm 10.2 ENO2 SYP
34 connective tissue benign neoplasm 10.2 ENO2 SYP
35 mixed cell type cancer 10.2 ENO2 SYP
36 glomus tumor 10.2 ENO2 SYP
37 intraocular retinoblastoma 10.2 ENO2 SYP
38 pineal parenchymal tumor of intermediate differentiation 10.2 ENO2 SYP
39 basaloid squamous cell carcinoma 10.2 ENO2 SYP
40 prostate small cell carcinoma 10.2 ENO2 SYP
41 cerebral primitive neuroectodermal tumor 10.2 ENO2 SYP
42 meningeal melanomatosis 10.2 ENO2 SYP
43 intracranial cysts 10.2 ENO2 GFAP
44 extraskeletal ewing sarcoma 10.2 ENO2 SYP
45 primitive neuroectodermal tumor of the cervix uteri 10.2 ENO2 GFAP
46 acute thyroiditis 10.2 CHGA ENO2
47 melanotic medulloblastoma 10.2 ENO2 GFAP
48 ureter small cell carcinoma 10.2 CHGA SYP
49 papilloma of choroid plexus 10.2 GFAP SYP
50 pineoblastoma 10.2 GFAP SYP

Graphical network of the top 20 diseases related to Subependymoma:



Diseases related to Subependymoma

Symptoms & Phenotypes for Subependymoma

UMLS symptoms related to Subependymoma:


headache, motor manifestations, sensory manifestations

MGI Mouse Phenotypes related to Subependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 AQP1 AQP4 ENO2 GFAP NCAM1 SYP
2 nervous system MP:0003631 9.56 AQP1 AQP4 CHGA ENO2 GFAP NCAM1
3 renal/urinary system MP:0005367 9.02 AQP1 AQP4 CHGA TRPS1 TSC2

Drugs & Therapeutics for Subependymoma

Drugs for Subependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Dopamine Approved Phase 3,Early Phase 1 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Cola Phase 3,Phase 1
7 Central Nervous System Depressants Phase 3
8 Adjuvants, Anesthesia Phase 3
9 Liver Extracts Phase 3,Phase 2,Phase 1
10 Anesthetics, Intravenous Phase 3
11 Analgesics, Opioid Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Anesthetics, General Phase 3
14 Analgesics Phase 3
15 Narcotics Phase 3
16 Anesthetics Phase 3
17 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1
18 Nootropic Agents Phase 3,Phase 2
19 Cholinergic Agents Phase 3,Phase 2
20 Cholinesterase Inhibitors Phase 3,Phase 2
21 Central Nervous System Stimulants Phase 3,Phase 2
22 Dopamine Agents Phase 3,Early Phase 1
23 Dexmethylphenidate Hydrochloride Phase 3
24 Neurotransmitter Uptake Inhibitors Phase 3
25 Dopamine Uptake Inhibitors Phase 3
26
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Bevacizumab Approved, Investigational Phase 2 216974-75-3
29
Armodafinil Approved, Investigational Phase 2 112111-43-0
30
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
31
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
32
Tamoxifen Approved Phase 2 10540-29-1 2733526
33
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
34
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
35
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
36
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
40
Promethazine Approved, Investigational Phase 2 60-87-7 4927
41
Acetaminophen Approved Phase 2 103-90-2 1983
42
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
45
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
46
Doxil Approved June 1999 Phase 2 31703
47 Alkylating Agents Phase 2,Phase 1
48 Antineoplastic Agents, Alkylating Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 2,Phase 1
50 Immunoglobulins Phase 2,Phase 1

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
5 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
6 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
7 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
8 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
9 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
10 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
11 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
12 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
13 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
14 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
15 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
16 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
18 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
19 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
21 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
22 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
23 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
24 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
25 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
26 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
27 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
28 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
29 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
30 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
31 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
32 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
33 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
34 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
35 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
36 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
37 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
38 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
39 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
40 Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Completed NCT00255671
41 Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma Completed NCT00005082 Not Applicable
42 Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting NCT01165632 Early Phase 1 fluorine F 18 fluorodopa
43 Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma Terminated NCT00430079 Not Applicable etanidazole
44 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
45 Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors Withdrawn NCT00005790 Not Applicable

Search NIH Clinical Center for Subependymoma

Genetic Tests for Subependymoma

Anatomical Context for Subependymoma

MalaCards organs/tissues related to Subependymoma:

41
Brain, Spinal Cord, T Cells, Bone, Lung, Liver, Ovary

Publications for Subependymoma

Articles related to Subependymoma:

(show top 50) (show all 144)
# Title Authors Year
1
Corrigendum to "Intratumoral Hemorrhage as an Unusual Manifestation of Intracranial Subependymoma" [World Neurosurg. (2018) 114:e647-e653]. ( 29887271 )
2018
2
Surgical management and long-term outcome of intracranial subependymoma. ( 29915887 )
2018
3
Spinal Cord Subependymoma Surgery : A Multi-Institutional Experience. ( 29526067 )
2018
4
Intratumoral Hemorrhage as an Unusual Manifestation of Intracranial Subependymoma. ( 29548959 )
2018
5
A symptomatic large subependymoma with neuroradiological features mimicking a high-grade glioma: A case report. ( 30060993 )
2018
6
Detection of H3K27 M mutation in cases of brain stem subependymoma. ( 30389438 )
2018
7
Apoplexy of a collision tumour composed of subependymoma and cavernous-like malformation in the lateral ventricle: a case report. ( 28992740 )
2017
8
Bilateral lateral ventricular subependymoma with extensive multiplicity presenting with hemorrhage. ( 28696174 )
2017
9
TRPS1 gene alterations in human subependymoma. ( 28528424 )
2017
10
Intracranial Subependymoma: A SEER Analysis 2004-2013. ( 28232153 )
2017
11
Anti-NMDAR encephalitis combined with a subependymoma. ( 28290412 )
2017
12
A Case of Intracranial Subependymoma: Histopathological Confirmation of Ring-shaped Lateral Ventricular Nodule. ( 28529248 )
2017
13
Bamboo Leaf Sign as a Sensitive Magnetic Resonance Imaging Finding in Spinal Subependymoma: Case Report and Literature Review. ( 28074165 )
2016
14
MR Spectroscopy to Distinguish between Supratentorial Intraventricular Subependymoma and Central Neurocytoma. ( 27941295 )
2016
15
Subependymoma with extensive microcystic transformation: a case report. ( 25973126 )
2015
16
Subependymoma of septum pellucidum presenting with cough and exertional headache: a case report of spontaneous regression after incomplete surgical removal. ( 25737362 )
2015
17
Recurrent subependymoma of fourth ventricle with unusual atypical histological features: A case report. ( 26059172 )
2015
18
Water Channels Aquaporin 4 and -1 Expression in Subependymoma Depends on the Localization of the Tumors. ( 26115524 )
2015
19
Erratum: Pedunculated intraventricular subependymoma: Review of the literature and illustration of classical presentation through a clinical case: Erratum. ( 26257982 )
2015
20
Surgical resection of subependymoma of the cervical spinal cord. ( 25175581 )
2014
21
Therapeutic targets in subependymoma. ( 25465288 )
2014
22
Intramedullary cervicothoracic subependymoma: report of three cases and review of the literature. ( 24842008 )
2014
23
Pedunculated intraventricular subependymoma: Review of the literature and illustration of classical presentation through a clinical case. ( 25101212 )
2014
24
Infratentorial and intraparenchymal subependymoma in the cerebellum: case report. ( 24497806 )
2014
25
Clinical, radiological, and pathological features in 43 cases of intracranial subependymoma. ( 25361493 )
2014
26
A case of septum pellucidum subependymoma with a subtle imaging appearance simulating a cavum septum pellucidum. ( 24421918 )
2013
27
Subependymoma causing conus-cauda syndrome: cured by total excision. ( 24441350 )
2013
28
Atypical hemorrhagic presentation of a fourth ventricle subependymoma: case report. ( 24140775 )
2013
29
Cytologic features of subependymoma with extensive microcystic transformation. ( 22045658 )
2013
30
Interesting case of subependymoma of the spinal cord. ( 24269267 )
2013
31
A 40-year-old male with an intraventricular tumor. Combined tanycytic ependymoma and subependymoma. ( 23587142 )
2013
32
Fourth ventricular subependymoma presenting as worsening headache. ( 23382616 )
2013
33
Thoracolumbar intramedullary subependymoma with multiple cystic formation: a case report and review. ( 22562689 )
2013
34
Supratentorial neurenteric cyst associated with a intraparenchymal subependymoma. ( 22891004 )
2012
35
Subependymoma: clinical features and surgical outcomes. ( 22747714 )
2012
36
Mirror image subependymoma. ( 23287356 )
2012
37
Cervical Subependymoma: A rare case report with possible histogenesis. ( 23189002 )
2012
38
Cerebellopontine angle subependymoma without fourth ventricle extension: an uncommon tumor in a rare location. ( 21692863 )
2012
39
Unusual appearance and presentation of supratentorial subependymoma in an adult patient. ( 23365712 )
2012
40
A rare case of subependymoma with an atypical presentation: a case report. ( 22121350 )
2011
41
Clinical features and management of five patients with supratentorial subependymoma. ( 20036555 )
2010
42
Intraoperative cytology of subependymoma. ( 20307001 )
2010
43
Spontaneous acute hemorrhage within a subependymoma of the lateral ventricle: successful emergent surgical removal through a frontal transcortical approach. ( 21165545 )
2010
44
Subependymoma at the foramen of Monro presenting with intermittent hydrocephalus: case report and review of the literature. ( 20882814 )
2010
45
Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage. ( 21123990 )
2010
46
Giant subependymoma developed in a patient with aniridia: analyses of PAX6 and tumor-relevant genes. ( 20500513 )
2010
47
Subependymoma of the spine. ( 20672503 )
2010
48
Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study. ( 20942580 )
2010
49
Subependymoma with prominent rosenthal fiber formation: case report. ( 21030810 )
2010
50
Bilateral bulbar palsy and postural hypotension following surgery for fourth ventricle subependymoma. ( 19766493 )
2009

Variations for Subependymoma

Expression for Subependymoma

Search GEO for disease gene expression data for Subependymoma.

Pathways for Subependymoma

Pathways related to Subependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 ENO2 GFAP NCAM1 SYP
2 11.41 AQP1 AQP4 GFAP
3 10.82 GFAP NCAM1 NES SYP

GO Terms for Subependymoma

Biological processes related to Subependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 renal water homeostasis GO:0003091 9.16 AQP1 AQP4
2 water transport GO:0006833 8.96 AQP1 AQP4
3 multicellular organismal water homeostasis GO:0050891 8.62 AQP1 AQP4

Molecular functions related to Subependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.16 AQP1 AQP4
2 water channel activity GO:0015250 8.96 AQP1 AQP4
3 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Subependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....